Eicosapentaenoic acid administration ameliorates the progression of liver fibrosis after laparoscopic Kasai portoenterostomy.

IF 1.5 3区医学 Q2 PEDIATRICS

Pediatric Surgery International Pub Date : 2024-08-21 DOI:10.1007/s00383-024-05800-2

Wataru Sumida, Takahisa Tainaka, Chiyoe Shirota, Satoshi Makita, Hizuru Amano, Akihiro Yasui, Takuya Maeda, Daiki Kato, Yosuke Goda, Hiroki Ishii, Kazuki Ota, Guo Yaohui, Liu Jiahui, Akinari Hinoki, Hiroo Uchida

{"title":"Eicosapentaenoic acid administration ameliorates the progression of liver fibrosis after laparoscopic Kasai portoenterostomy.","authors":"Wataru Sumida, Takahisa Tainaka, Chiyoe Shirota, Satoshi Makita, Hizuru Amano, Akihiro Yasui, Takuya Maeda, Daiki Kato, Yosuke Goda, Hiroki Ishii, Kazuki Ota, Guo Yaohui, Liu Jiahui, Akinari Hinoki, Hiroo Uchida","doi":"10.1007/s00383-024-05800-2","DOIUrl":null,"url":null,"abstract":"Purpose: Biliary atresia (BA) poses a persistent challenge characterized by ongoing liver inflammation and subsequent fibrosis even after the clearance of jaundice (COJ). This study aimed to evaluate the therapeutic potential of eicosapentaenoic acid (EPA) in alleviating liver inflammation and limiting fibrosis during the post-COJ phase of BA.Methods: Among the BA patients undergoing laparoscopic Kasai portoenterostomy (lapKP) between December 2016 and October 2021, EPA (20-40 mg/kg/day) was administered orally to those whose parents consented. The study included patients from January 2014 to October 2021, classifying them into two groups: EPA-treated (Group E) and untreated (Group N). Their liver fibrosis and clinical course at 1 and 2 years post-lapKP were compared.Results: Group E consisted of 25 patients, while Group N comprised 32 patients. Twenty-one patients in Group E and 25 patients in Group N achieved COJ (p = 0.74). Among jaundice-free patients at 1 and 2 years post-lapKP, Group E exhibited significantly lower M2BPGi levels and platelet counts, and Group E showed a significant reduction in Aminotransferase-to-Platelet Ratio Index (APRI) at 2 years post-lapKP.Conclusion: Although EPA administration did not improve COJ, it attenuated the progression of liver fibrosis during the 2 years following lapKP in jaundice-free patients. (200/200Words).","PeriodicalId":19832,"journal":{"name":"Pediatric Surgery International","volume":"40 1","pages":"239"},"PeriodicalIF":1.5000,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11339178/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Surgery International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00383-024-05800-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PEDIATRICS","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Biliary atresia (BA) poses a persistent challenge characterized by ongoing liver inflammation and subsequent fibrosis even after the clearance of jaundice (COJ). This study aimed to evaluate the therapeutic potential of eicosapentaenoic acid (EPA) in alleviating liver inflammation and limiting fibrosis during the post-COJ phase of BA.

Methods: Among the BA patients undergoing laparoscopic Kasai portoenterostomy (lapKP) between December 2016 and October 2021, EPA (20-40 mg/kg/day) was administered orally to those whose parents consented. The study included patients from January 2014 to October 2021, classifying them into two groups: EPA-treated (Group E) and untreated (Group N). Their liver fibrosis and clinical course at 1 and 2 years post-lapKP were compared.

Results: Group E consisted of 25 patients, while Group N comprised 32 patients. Twenty-one patients in Group E and 25 patients in Group N achieved COJ (p = 0.74). Among jaundice-free patients at 1 and 2 years post-lapKP, Group E exhibited significantly lower M2BPGi levels and platelet counts, and Group E showed a significant reduction in Aminotransferase-to-Platelet Ratio Index (APRI) at 2 years post-lapKP.

Conclusion: Although EPA administration did not improve COJ, it attenuated the progression of liver fibrosis during the 2 years following lapKP in jaundice-free patients. (200/200Words).

Abstract Image

查看原文本刊更多论文

服用二十碳五烯酸可改善腹腔镜卡萨伊肠造口术后肝纤维化的进展。

目的：胆道闭锁（BA）是一项持久性挑战，其特点是即使在黄疸清除（COJ）后仍存在持续的肝脏炎症和随后的纤维化。本研究旨在评估二十碳五烯酸（EPA）在减轻 BA 后 COJ 阶段肝脏炎症和限制纤维化方面的治疗潜力：在2016年12月至2021年10月期间接受腹腔镜葛西肠管造口术（lapKP）的BA患者中，对父母同意的患者口服EPA（20-40 mg/kg/天）。该研究纳入了2014年1月至2021年10月的患者，将他们分为两组：EPA治疗组（E组）和未治疗组（N组）。比较了他们的肝纤维化情况以及肝硬化术后1年和2年的临床病程：结果：E 组有 25 名患者，N 组有 32 名患者。E 组和 N 组分别有 21 名和 25 名患者达到 COJ（P = 0.74）。在腹腔镜手术后 1 年和 2 年无黄疸的患者中，E 组的 M2BPGi 水平和血小板计数显著降低，E 组在腹腔镜手术后 2 年的转氨酶与血小板比率指数（APRI）显著降低：结论：虽然服用 EPA 并不能改善无黄疸患者的 COJ，但它能减轻无黄疸患者在腹腔镜手术后 2 年内肝纤维化的进展。(200/200字）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatric Surgery International 医学-外科

CiteScore

3.00

自引率

5.60%

发文量

215

审稿时长

3-6 weeks

期刊介绍： Pediatric Surgery International is a journal devoted to the publication of new and important information from the entire spectrum of pediatric surgery. The major purpose of the journal is to promote postgraduate training and further education in the surgery of infants and children. The contents will include articles in clinical and experimental surgery, as well as related fields. One section of each issue is devoted to a special topic, with invited contributions from recognized authorities. Other sections will include: -Review articles- Original articles- Technical innovations- Letters to the editor